CHMP minded to turn down Alzheimer’s drug Aduhelm, says BiogenBiogen and Eisai have said that the EMA’s human medicines committee looks unlikely recommended approval of their Alzheimer’s Share XCHMP minded to turn down Alzheimer’s drug Aduhelm, says Biogenhttps://pharmaphorum.com/news/chmp-minded-to-turn-down-alzheimers-drug-aduhelm-says-biogen/
AbbVie’s Humira tops ICER’s list of unwarranted price hikes againWith drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Share XAbbVie’s Humira tops ICER’s list of unwarranted price hikes againhttps://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/
In shock move, Biogen chief medical officer Al Sandrock will stand downBiogen’s chief medical officer Al Sandrock has announced he will retire at the end of the year, ending Share XIn shock move, Biogen chief medical officer Al Sandrock will stand downhttps://pharmaphorum.com/news/in-shock-move-biogen-chief-medical-officer-al-sandrock-will-stand-down/
Lilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialEli Lilly has followed through on its plan to file for approval of its Alzheimer’s disease candidate donanemab, Share XLilly files Alzheimer’s drug donanemab as Cortexyme rival fails trialhttps://pharmaphorum.com/news/lilly-files-alzheimers-drug-donanemab-as-cortexyme-rival-fails-trial/
Early diagnosis key to future Alzheimer’s treatmentsThe approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, Share XEarly diagnosis key to future Alzheimer’s treatmentshttps://pharmaphorum.com/r-d/early-diagnosis-key-to-future-alzheimers-treatments/
Biogen’s Aduhelm rollout goes from bad to worseAnalysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum Share XBiogen’s Aduhelm rollout goes from bad to worsehttps://pharmaphorum.com/news/biogens-aduhelm-rollout-goes-from-bad-to-worse/
Biogen, Sage prep 2022 filing for depression drug zuranoloneThe renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to Share XBiogen, Sage prep 2022 filing for depression drug zuranolonehttps://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/
Blow to Biogen as ALS hope tofersen flunks phase 3 trialAlready struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback Share XBlow to Biogen as ALS hope tofersen flunks phase 3 trialhttps://pharmaphorum.com/news/blow-to-biogen-as-als-hope-tofersen-flunks-phase-3-trial/
Biogen, Eisai double down on Alzheimer’s with lecanemab filingBiogen and Eisai’s first Alzheimer’s disease drug Aduhelm is facing an uphill battle in the US market, but Share XBiogen, Eisai double down on Alzheimer’s with lecanemab filinghttps://pharmaphorum.com/news/biogen-eisai-double-down-on-alzheimers-with-lecanemab-filing/
